Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Revenue for 5 consecutive years, with $202.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 64.95% year-over-year to $202.1 million, compared with a TTM value of $677.6 million through Dec 2025, up 60.09%, and an annual FY2025 reading of $677.6 million, up 60.09% over the prior year.
  • Revenue was $202.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $180.9 million in the prior quarter.
  • Across five years, Revenue topped out at $202.1 million in Q4 2025 and bottomed at -$148.3 million in Q4 2022.
  • Average Revenue over 5 years is $78.4 million, with a median of $81.6 million recorded in 2023.
  • Peak annual rise in Revenue hit 719.64% in 2022, while the deepest fall reached 891.12% in 2022.
  • Year by year, Revenue stood at $18.7 million in 2021, then plummeted by 891.12% to -$148.3 million in 2022, then skyrocketed by 156.24% to $83.4 million in 2023, then soared by 46.93% to $122.5 million in 2024, then skyrocketed by 64.95% to $202.1 million in 2025.
  • Business Quant data shows Revenue for KNSA at $202.1 million in Q4 2025, $180.9 million in Q3 2025, and $156.8 million in Q2 2025.